Biosceptre
Julian leads Biosceptre’s therapeutic discovery efforts. Following a 30 year research career, his research focused on the structure and function of the family of purinergic receptors of type P2X and their role in disease, including cancer. Discoveries within the field led to the numerous patent families now held by Biosceptre, encompassing diagnostic and therapeutic elements, chief among many being the discovery of the cancer target nfP2X7.
This person is not in any offices
Biosceptre
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue.